Global Biopsy Guns and Needles Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Biopsy Guns and Needles Market Analysis

The biopsy guns and needles market has seen notable advancements in recent years, driven by innovations in technology and improved methods for more accurate diagnostics. One significant technological advancement is the development of automated biopsy guns that offer higher precision and faster tissue sampling with minimal pain for patients. These guns now come with features such as adjustable trigger mechanisms and improved safety features, allowing healthcare professionals to perform biopsies with greater control and less discomfort.

Another key development is the integration of imaging technologies, such as ultrasound and MRI guidance, into biopsy needles. This enhances the accuracy of the needle placement, ensuring that tissue samples are taken from the right area, especially in challenging cases such as tumors in deep tissues.

The market is also witnessing a shift toward biopsy needles with advanced coatings that reduce tissue trauma and promote faster healing. As these technologies become more refined, the biopsy guns and needles market is growing, driven by the increasing demand for minimally invasive diagnostic procedures, particularly in oncology. The market is expected to expand significantly with the rise of personalized medicine and early disease detection.

Biopsy Guns and Needles Market Size

The global biopsy guns and needles market size was valued at USD 124.19 million in 2024 and is projected to reach USD 168.39 million by 2032, with a CAGR of 3.88% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Biopsy Guns and Needles Market Trends

“Increasing Demand for Minimally Invasive Procedures”

One specific trend driving growth in the biopsy guns and needles market is the rising demand for minimally invasive procedures. Patients and healthcare providers are increasingly opting for less invasive methods due to their associated benefits, such as shorter recovery times, reduced pain, and fewer complications. Biopsy guns and needles are crucial in performing these procedures, offering precise tissue sampling with minimal discomfort. For instance, innovations in core biopsy needles, such as the automated systems developed by companies such as Cook Medical, are enhancing the accuracy and efficiency of cancer diagnostics, further supporting the shift toward minimally invasive practices and contributing to market expansion.

Report Scope and Biopsy Guns and Needles Market Segmentation  

Biopsy Guns and Needles Market Definition

Biopsy guns and needles are medical devices used to collect tissue samples for diagnostic purposes, primarily in detecting diseases such as cancer. The biopsy gun is a spring-loaded instrument designed to quickly and precisely insert a needle into the tissue to retrieve a sample. The needle is typically hollow, allowing it to collect the tissue core for examination. Biopsy guns are often used in procedures involving organs such as the breast, liver, or prostate. These tools enable minimally invasive tissue collection with reduced patient discomfort, providing essential information for accurate diagnosis and treatment planning.

Biopsy Guns and Needles Market Dynamics

Drivers

• Increasing Cancer Prevalence

The rising incidence of cancers, particularly breast, prostate, and lung cancers, is a significant driver for the biopsy guns and needles market. As these cancers require early detection and accurate diagnosis, the demand for biopsy procedures has surged. For instance, According to the World Health Organization, cancer ranks as the second leading cause of death in the region. Each year, the disease significantly impacts public health, with over 3.7 million new cases diagnosed and approximately 1.9 million fatalities reported. These statistics underline the urgent need for effective prevention, early detection, and treatment strategies to combat cancer.

• Rising Demand for Precision Medicine

The growing emphasis on precision medicine, which tailors treatments based on individual genetic profiles, is a significant driver for the biopsy guns and needles market. Precision medicine requires highly accurate and timely tissue samples to analyze genetic mutations and biomarkers, making biopsy procedures essential. For instance, in oncology, precision medicine has revolutionized cancer treatment, where targeted therapies are often based on biopsy results. The need for minimally invasive, precise sampling methods, such as those offered by advanced biopsy guns and needles, ensures quick and reliable diagnostic outcomes, supporting personalized treatment plans. This shift toward precision medicine continues to drive the adoption of advanced biopsy technologies in clinical settings.

Opportunities

• Advancements in Diagnostic Techniques

Technological innovations in biopsy procedures, particularly image-guided techniques such as ultrasound, MRI, and CT-guided biopsies, have significantly improved accuracy and efficiency. These advancements allow clinicians to precisely target areas of concern, minimizing tissue damage and improving diagnostic outcomes. For instance, the integration of biopsy guns with real-time imaging technologies has made procedures more efficient, reducing the number of needle passes needed and enhancing tissue sample quality. This shift towards more accurate, less invasive techniques is driving the adoption of advanced biopsy needles and guns, creating lucrative opportunities for manufacturers. As diagnostic precision becomes more critical in personalized medicine, the demand for these advanced tools continues to rise.

• Improved Needle Design and Technology

Innovations in needle design and technology present significant opportunities in the biopsy guns and needles market. The development of finer gauge needles, such as those with smaller diameters, reduces patient discomfort and minimizes tissue damage, creating demand for more efficient and less invasive procedures. Automated biopsy guns, which enable faster and more accurate tissue sampling, are increasingly popular in clinical settings. For instance, devices such as the Bard Magnum Core Biopsy Gun are equipped with advanced features, including automated firing mechanisms and ergonomic designs, improving precision and reducing procedural errors. These advancements enhance patient satisfaction and increase adoption rates, opening new avenues for growth in the market.

Restraints/Challenges

• Risk of Complications

Biopsy procedures involve invasive techniques that carry inherent risks, which hinder market growth. While complications are uncommon, they can include infections, significant bleeding, or accidental injury to surrounding tissues. These risks create apprehension among patients and healthcare providers, often leading to reluctance in choosing such procedures. The fear of adverse outcomes can impact patient compliance and limit the widespread adoption of biopsy tools, particularly in sensitive cases. Moreover, concerns over legal and ethical implications related to procedural risks further deter healthcare facilities from readily embracing biopsy technologies. These factors collectively impede the expansion of the biopsy guns and needles market.  

• Lack of Skilled Professionals

Biopsy procedures demand precision and expertise, typically requiring skilled professionals such as radiologists or pathologists to ensure accuracy. However, many regions, especially in low- and middle-income countries, face a significant shortage of trained personnel. This scarcity affects the availability and quality of biopsy services, leading to delayed diagnoses or errors in procedures. In addition, the lack of adequate training programs further exacerbates the problem, creating a widening gap between the demand for biopsies and the supply of qualified professionals. This challenge directly hinders the growth of the biopsy guns and needles market by limiting their usage and accessibility in underserved areas.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Biopsy Guns and Needles Market Scope

The market is segmented on the basis of product type, technique, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Disposable
• Reusable

Technique

• Ultrasound-Guided Biopsy
• Stereotactic-Guided Biopsy
• MRI-Guided Biopsy
• Others

 Application

• Breast Biopsy
• Lung Biopsy
• Colorectal Biopsy
• Prostate Biopsy
• Others

 End User

• Hospitals
• Academic and Research Institutes
• Diagnostic and Imaging Centers
• Others

Biopsy Guns and Needles Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product type, technique, application and end user as referenced above.

The countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, U.A.E, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)

North America is expected to dominate the biopsy guns and needles market due to increased research and development investments and a growing prevalence of cancer, particularly in developed nations such as the U.S. Advanced healthcare infrastructure and supportive government initiatives further drive the adoption of these diagnostic tools, boosting market growth in the region.

Asia-Pacific is expected to expand at a significant growth rate in the biopsy guns and needles market due to rising awareness about early cancer detection through biopsy procedures. In addition, the increasing aging population, which is more susceptible to chronic diseases, further boosts demand, driving market expansion across the region during the forecast period.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Biopsy Guns and Needles Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Biopsy Guns and Needles Market Leaders Operating in the Market Are:

• Cardinal Health (U.S.)
• BD (U.S.)
• Medax SRL (Italy)
• Möller Medical GmbH (Germany)
• ARGON MEDICAL (U.S.)
• DTR Medical Ltd. (U.K.)
• Hologic, Inc. (U.S.)
• INRAD, Inc. (U.S.)
• Cook (U.S.)
• B. Braun SE (Germany)
• Olympus Corporation (Japan)
• Boston Scientific Corporation (U.S.)
• Merit Medical Systems (U.S.)
• Ranfac Corp. (U.S.)
• FUJIFILM Corporation (Japan)
• Medtronic (Ireland)
• CONMED Corporation (U.S.)
• Stryker (U.S.)
• SOMATEX Medical Technologies GmbH (Germany)

Latest Developments in Biopsy Guns and Needles Market

• In April 2024, Single Pass achieved a milestone with FDA clearance for its Kronos biopsy closure device, a Class II medical device. The Kronos device aims to simplify post-biopsy procedures, enhancing patient outcomes and operational efficiency for healthcare providers
• In May 2023, Argon Medical Devices launched the SuperCore Advantage semi-automatic biopsy instrument in the U.S. Designed for soft tissue biopsies, this innovative device combines precision and ease of use, streamlining procedures in diagnostic medicine
• In February 2023, TransMed7 revealed plans to introduce advanced ultrasound-guided biopsy devices. This development underscores their commitment to providing minimally invasive and accurate biopsy solutions for improved diagnostic accuracy
• In December 2022, Olympus finalized the acquisition of Odin Medical Ltd., a UK-based cloud-AI endoscopy company. Conducted via Keymed, its UK subsidiary, the move integrates AI-driven diagnostic tools into Olympus' portfolio, advancing healthcare imaging technology
• In November 2021, B. Braun and REVA Medical announced a partnership for the distribution of Fantom Encore, a bioresorbable scaffold for coronary interventions. Manufactured with REVA's Tyrocore material, distribution began in Germany and Switzerland, with plans for broader reach
• In June 2021, Saga Surgical, a Swedish company, introduced the Forsvall Needle, an innovative biopsy needle designed to reduce risks of sepsis or infection post-procedure. This advancement aligns with the growing focus on safety in diagnostic practices

SKU-63919